Business Wire

CA-OPTIV-SECURITY

6.3.2019 16:07:03 CET | Business Wire | Press release

Share
Optiv Security Announces New Risk Transformation Service™ to Help Organizations Mitigate Enterprise Risk

Most organizations conduct annual risk assessments, identify gaps, and receive recommendations for how to remediate those gaps. But many lack the resources to follow through on planning and operationalization. Based on strategies developed or assessments performed, many organizations know what to do but often not how to do it. Optiv Security , the world’s leading security solutions integrator, today announced its new Risk Transformation ServiceTM , an end-to-end solution that includes strategy execution.

Designed to enable clients around the world to better evaluate current risk against acceptable risk, Optiv’s Risk Transformation ServiceTM helps clients develop strategies that drive cohesive cybersecurity programs, execute on those strategies to mitigate enterprise risk, and achieve measurable outcomes. The service puts business strategy and risk at the heart of cyber decision-making with two distinct options:

  • The Enterprise Risk Transformation Service TM helps organizations execute on risk transformation based on business objectives, results of an existing strategy or assessment, and a list of desired improvements or future mode of operation. This service includes program management, quality assurance and oversight over all or parts of a transformation or remediation initiative.
  • The Quickstart Risk Transformation Service TM enables mid-sized organizations to get started with a risk-centric model for cybersecurity and aids them in the first steps of execution of their transformation roadmap. Optiv helps these clients set and execute a strategy, engaging with them from start to finish.

“Organizations today are adopting new risk and compliance principles to achieve business resilience,” said Dustin Owens, Optiv’s vice president, risk advisory. “As IT risk management evolves to more holistic operational risk management, it is being integrated into the fabric of organizations. This means that security teams are now a critical component to the overall business risk strategy.”

Owens continued, “As a result, adaptive, risk-based decision-making is becoming core to business agility and resilience, taking over from the antiquated check-the-box, compliance-based approach of the past. It’s high time for companies to embrace the risk revolution. They need to take a stance against the outside-in approach – which is predicated on continuously responding to legislative and regulatory requirements, specific threats, and other outside factors – and rewrite how they manage cybersecurity by proactively addressing all aspects of cybersecurity risk, including privacy and governance , cyber resilience, and risk optimization.”

Optiv’s new Risk Transformation ServiceTM is part of the company’s complete continuum of fully integrated cybersecurity risk services, which are focused on resolving three prevalent business issues:

  • The need for risk governance – Optiv helps clients understand where critical assets are located, why they are important, how they are protected and who has access; and as these variables change, how their risk profile changes. This enables organizations to make security decisions based on risk so they can move faster, safely.
  • Volume and velocity of change – Optiv allows clients to embrace the fast pace of digital transformation initiatives and deal with constant operational chaos simultaneously by helping them execute adaptive cyber resilience capabilities.
  • Articulating security health to the business and board – Optiv provides security teams with everything they need to articulate risk and security performance in business terms by enabling them to effectively measure, monitor and report on security posture and align security to business objectives. This allows security teams to influence better decision-making and improve overall business health.

Please visit Optiv’s website to learn more about risk transformation or the company’s overarching approach to risk management .

Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn: www.linkedin.com/company/optiv-inc
Facebook: www.facebook.com/optivinc
YouTube: www.youtube.com/c/OptivInc
Blog: www.optiv.com/explore-optiv-insights/blog

About Optiv Security

Optiv helps clients plan, build and run successful cybersecurity programs that achieve business objectives through our depth and breadth of cybersecurity offerings, extensive capabilities and proven expertise in cybersecurity, integration and cyber operational services. Optiv maintains premium partnerships with more than 350 of the leading cybersecurity technology manufacturers. For more information, visit www.optiv.com .

Contact:

Brett Ater (913) 304-7683 Brett.ater@optiv.com or Jason Cook (816) 701-3374 Jason.cook@optiv.com

Link:

ClickThru

Social Media:

https://www.facebook.com/OptivInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye